Tan, Carlyn Rose http://orcid.org/0000-0001-7922-2594
Derkach, Andriy http://orcid.org/0000-0003-2178-8493
Nemirovsky, David
Ciardiello, Amanda
Diamond, Benjamin
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Hassoun, Hani http://orcid.org/0000-0002-2036-1749
Mailankody, Sham http://orcid.org/0000-0002-2815-9561
Shah, Urvi http://orcid.org/0000-0001-8419-1091
Maclachlan, Kylee http://orcid.org/0000-0001-7873-4854
Patel, Dhwani
Lahoud, Oscar B. http://orcid.org/0000-0002-3291-286X
Landau, Heather J. http://orcid.org/0000-0002-3152-1189
Chung, David J. http://orcid.org/0000-0003-0469-839X
Shah, Gunjan L. http://orcid.org/0000-0002-9977-0456
Scordo, Michael
Giralt, Sergio A. http://orcid.org/0000-0003-1944-5053
Lesokhin, Alexander
Usmani, Saad Z.
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Korde, Neha
Funding for this research was provided by:
Memorial Sloan Kettering NIH/NCI Cancer Center Support Grant
Article History
Received: 21 February 2023
Revised: 17 June 2023
Accepted: 11 July 2023
First Online: 25 July 2023
Competing interests
: CT reports research funding from Janssen and Takeda and personal fees from MJH Life Sciences; has participated in advisory boards for Janssen and Sanofi, outside of the submitted work. BD reports honoraria received from Janssen and Sanofi, outside the submitted work. MH reports research funding from Amgen, Daiichi Sankyo, GlaxoSmithKline; and has received honoraria for consultancy/participated in advisory boards for Curio Science LLC, Intellisphere LLC, Bristol Myer Squibb, and GlaxoSmithKline. HH reports grants from Celgene, Takeda, and Janssen, outside the submitted work. SM reports consulting fees from Evicore, Optum, BioAscend, Janssen Oncology and Legend Biotech. Memorial Sloan Kettering Cancer Center receives research funding from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics and Takeda Oncology for conducting research. SM received honoraria from OncLive, Physician Education Resource, MJH Life Sciences and Plexus Communications, outside the submitted work. US reports research funding from Celgene/Bristol Myers Squibb and Janssen; personal fees from Janssen, Sanofi, Bristol Myers Squibb; and honoraria for continuing medical education activity from MJH Life Sciences, MashUpMD, and ACCC, outside the submitted work. KM reports grant support from ASH, MMRF, and IMS. OBL reports serving on an advisory board for MorphoSys Inc and Kite. HJL reports research funding from Alexion Pharmaceuticals, Takeda, Janssen, Prothena, and Protego; and has received honoraria for consultancy/participated in advisory boards for Karyopharm, Pfizer, Juno, Prothena, Caelum Biosciences, Legend Biotech, Takeda, Janssen, and Nexcella. GLS reports research funding from Janssen, Amgen, BMS, Beyond Spring, and serves on the Data Safety Monitoring Board for ArcellX. MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, and Amgen, Inc.; served on ad hoc advisory boards for Kite – A Gilead Company; and received honoraria from i3Health, Medscape, and CancerNetwork for CME-related activity. SAG reports personal fees and advisory role (scientific advisory board) from Actinium, Celgene, Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite, outside the submitted work. AL reports grants from Bristol Myers Squibb; grants, personal fees and non-financial support from Pfizer; and grants and personal fees from Janssen, outside the submitted work. AL serves on the Data Safety Monitoring Board for ArcellX and also has a patent US20150037346A1 with royalties paid. SZU received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda, is a Consultant to Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio, and is also a Speaker with Amgen, BMS, Janssen, Sanofi. OL has received grant support from LLS, Rising Tide Foundation, NIH, FDA, MMRF, IMF, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by Takeda, Merck, Janssen, Theradex. NK reports research funding through Amgen, Janssen, Epizyme, AbbVie; consults for CCO, OncLive, and Intellisphere Remedy Health; and participated in advisory board for Janssen.